

## ERA<sup>®</sup> is a diagnostic test patented by Igenomix in 2009



3 in every 10 patients  
have a displaced WOI

ERA analyzes 248 genes  
related to endometrial receptivity

## pET | Personalized Embryo Transfer

	pET CLINICAL OUTCOME		
	RECEPTIVE	CORRECTION	TOTAL
NUMBER OF PET PERFORMED	215	297	512
IMPLANTATION RATE	56.3% (166/295)	58.2% (216/371)	57.4% (382/666)
PREGNANCY RATE	73% (157/215)	72.7% (216/297)	72.9% (373/512)
BIOCHEMICAL PREGNANCY	9.6% (15/157)	10.6% (23/216)	10.2% (38/373)
MISCARRIAGE	11.5% (18/157)	12% (26/216)	11.8% (44/373)
ECTOPIC	0.6% (1/157)	0.5% (1/216)	0.5% (2/373)
ONGOING / PREGNANCY	78.3% (123/157)	76.9% (166/216)	77.5% (289/373)
ONGOING / PET	57.2% (123/215)	55.9% (166/297)	56.4% (289/512)


## ERA<sup>®</sup> Results

### Personalized embryo transfer (pET) according to ERA<sup>®</sup>

Indicated for recurrent implantation failure (RIF)



- Days with ESTRADIOL VALERATE
- Days with PROGESTERONE



## Why choose Igenomix's ERA test?



- **ERA is backed by 33 publications** 29 from Igenomix and 4 external publications.



- Randomized study in progress to assess its **applicability in patients without any prior ART.**

(ClinicalTrials.gov Identifier: NCT01954758)



- **Proprietary algorithm based on over a decade of extensive research.**



- **ERA allows clinicians to identify transition phases with 12 hours shifts.**

## When is a second biopsy needed?

90 % of cases don't need a second biopsy. The second biopsy is only required under two circumstances:

- Patients with a "Pre-receptive 2 days" result.
- Patients with a "Post-receptive" result.

### IGENOMIX DATA

